KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ginkgo Bioworks Holdings (DNA) Accumulated Expenses (2020 - 2025)

Ginkgo Bioworks Holdings' Accumulated Expenses history spans 6 years, with the latest figure at $66.5 million for Q4 2025.

  • For Q4 2025, Accumulated Expenses rose 1.64% year-over-year to $66.5 million; the TTM value through Dec 2025 reached $66.5 million, up 1.64%, while the annual FY2025 figure was $66.5 million, 1.64% up from the prior year.
  • Accumulated Expenses reached $66.5 million in Q4 2025 per DNA's latest filing, down from $79.3 million in the prior quarter.
  • In the past five years, Accumulated Expenses ranged from a high of $122.6 million in Q1 2023 to a low of $53.6 million in Q3 2021.
  • Average Accumulated Expenses over 5 years is $88.4 million, with a median of $84.0 million recorded in 2022.
  • Peak YoY movement for Accumulated Expenses: skyrocketed 205.96% in 2021, then tumbled 51.13% in 2025.
  • A 5-year view of Accumulated Expenses shows it stood at $93.3 million in 2021, then increased by 22.89% to $114.7 million in 2022, then decreased by 4.05% to $110.1 million in 2023, then crashed by 40.58% to $65.4 million in 2024, then grew by 1.64% to $66.5 million in 2025.
  • Per Business Quant, the three most recent readings for DNA's Accumulated Expenses are $66.5 million (Q4 2025), $79.3 million (Q3 2025), and $57.2 million (Q2 2025).